AstraZeneca’s COVID-19 vaccine
U.K. regulator granted emergency use authorisation of AstraZenca's Vaccine on 30.12.20
It is based on weakened Adenovirus, i.e. a common cold flu virus which contains genetic material of spike protein.
Can be stored and transported at 2°- 8°.
less costly then mRNA Vaccines like that of Pfizer and Moderna.
Showed 62% efficacy when 2 full strength dose administered 4 weeks apart, as per published report.
Comments
Post a Comment